Quote this publication Share Print

JAKAVI (ruxolitinib), protein kinase inhibitor

Opinions on drugs - Posted on May 10 2017

Reason for request

Nouvel examen suite au dépôt de nouvelles données

Moderate clinical added value in the management of myelofibrosis.


  • Since 2012, JAKAVI has had marketing authorisation in the treatment of splenomegaly or symptoms related to primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis.
  • Its efficacy has been established based on reduction in spleen volume and on the resulting symptoms.
  • The new data do not change the previous assessment: JAKAVI provides moderate clinical added value in its indication.


Clinical Benefit



Clinical Added Value



Therapeutic use




Contact Us

Évaluation des médicaments